This method accounted for factors such as age, gender, race, comorbidities, medications, and laboratory data, including HbA1c, blood pressure, lipids, and BMI to provide insights into their roles as risk factors in the outcomes of interest
By identifying key factors such as age, race, T2D duration, HbA1C levels, BMI, hypertension, and the presence of other conditions like heart failure or retinopathy, our model provides a personalized tool for clinicians to make informed treatment decisions
We excluded individuals prescribed with GLP-1 RAs or SGLT-2 inhibitors before index date in the GLP-1 RA vs
Documentation Summary for CDI Obesity Encounter Checklist For additional guidance on obesity coding, refer to the FY2026 ICD-10-CM Official Guidelines (CMS), the AHA Coding Clinic, and the American Society for Metabolic and Bariatric Surgery (ASMBS) clinical guidelines
About Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) Key Stats Today's Range $32.40 $32.62 50-Day Range $29.78 $33.99 52-Week Range $23.22 $37.15 Volume 10,367 shs Average Volume 25,881 shs Market Capitalization $62.78 million Assets Under Management N/A Dividend Yield N/A Net Expense Ratio 0.59% Aggregate Rating Moderate Buy ETF Overview Roundhill GLP-1 & Weight Loss ETF Expenses Receive OZEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roundhill GLP-1 & Weight Loss ETF and its competitors with MarketBeat's FREE daily newsletter
McCarberg BH
